2076975 2077203
최종편집 2021-12-05 07:32 (일)
KOSPI Q3 earnings ranking, Samsung Biologics in 103rdㆍYuhan Corporation in 107th
상태바
KOSPI Q3 earnings ranking, Samsung Biologics in 103rdㆍYuhan Corporation in 107th
  • Hyeokgi Lee, Newsmp
  • 승인 2021.11.23 03:34
  • 댓글 0
이 기사를 공유합니다

Green Cross 119thㆍChong Kun Dang Pharmaceutical 128thㆍCelltrion 132nd, 5 companies     entered Top 150

In the third quarter, 10 out of 662 KOSPI-listed (excluding finance industry) pharmaceutical firms whose closing account is at the end of December ranked in the top 200 in earnings ranking (based on individual financial statements).

None of the companies placed in the top 100 in sales in the pharmaceutical industry, but 10 firms were listed between 100 and 200, according to Korea Exchange.

Samsung Biologics took the lead with a 103rd-place with sales of KRW 450.7 billion, surpassing Yuhan Corporation.

Yuhan Corporation ranked 107th with more than KRW 400 billion with KRW 436.4 billion, Green Cross Corporation in 119th with KRW 377.3 billion, Chong Kun Dang Pharmaceutical in 128th with KRW 341.3 billion, and Celltrion in 132nd with KRW 332.5 billion.

Daewoong Pharmaceutical placed 155th with KRW 265.1 billion, Kwang Dong Pharmaceutical 175th with KRW 228.8 billion, Hanmi Pharmaceutical 176th with KRW 226.2 billion, SK Bioscience 180th with KRW 220.8 billion, and Jeil Pharmaceutical 195th with KRW 181.7 billion.

Followed by the leaders, Boryung Pharmaceutical, Dong-A ST, JW Pharmaceutical, Ildong Pharmaceutical, and Handok, with sales of KRW 100 billion mark were placed between 200 and 300.

Companies with between KRW 50 billion and KRW 100 billion in sales, including Daewon Pharmaceutical, Samjin Pharmaceutical, Il-Yang Pharmaceutical, Dongwha Pharm, and United Pharmaceuticals, were placed in 300 to 400.

Hana Pharm, Yungjin Pharmaceuticals, Bukwang Pharmaceutical, Shinpoong Pharmaceutical, Whanin Pharmaceutical, Kyongbo Pharmaceutical, CKD Bio, Reyon Pharmaceutical, Samil Pharmaceutical, and Myungmoon Pharm. were in the top 500 with more than KRW 30 billion.

Moreover, Kukje Pharma, PharmGen Science, HanAll Biopharma, Yuyu Pharma, Dongsung Pharmaceutical, Pharmicell, Ilsung Pharmaceutical, Samsung Pharm., Aprogen Pharmaceuticals, GeneOne Life Science, Chong Kun Dang Holdings, and Ildong Holdings fell out of the top 500 with less than KRW 30 billion in sales.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.